Exploiting Homeostatic Repopulation to Increase DC Vaccine Efficacy in Multiple Myeloma

Chandler D. Gatenbee; Núria Folguera-Blasco; Charlie Daneils; Jill Gallaher; Russell C. Rockne; Casey Adams; Michael Nicholson; Eleni Maniati; John Kennedy; Kimberly Luddy; Frederick L. Locke; Mark Robertson-Tessi

doi:10.1101/049072

Cancer BiologybioRxivApr 22, 2016

Preprint

Exploiting Homeostatic Repopulation to Increase DC Vaccine Efficacy in Multiple Myeloma

Chandler D. Gatenbee, Núria Folguera-Blasco, Charlie Daneils, Jill Gallaher, Russell C. Rockne iD, Casey Adams, Michael Nicholson, Eleni Maniati, John Kennedy, Kimberly Luddy, Frederick L. Locke, Mark Robertson-Tessi

Abstract

Standard of care for multiple myeloma involves autologous hematopoietic cell transplant (AHCT), which can extend life by a year; however the disease remains incurable. A dendritic cell vaccine developed at Moffitt will be used both immediately before and after AHCT, with the aim of achieving complete response. Data will be collected during the trial to test the biological activity of the vaccine. This data will parameterize a model that facilitates the exploration of outcomes when varying the timing of vaccination. This calibrated model will also inform the design of a follow-up trial, which will include vaccination in conjunction with other immunotherapies.

PDF DOI